BR112021012240A2 - Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich - Google Patents
Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrichInfo
- Publication number
- BR112021012240A2 BR112021012240A2 BR112021012240A BR112021012240A BR112021012240A2 BR 112021012240 A2 BR112021012240 A2 BR 112021012240A2 BR 112021012240 A BR112021012240 A BR 112021012240A BR 112021012240 A BR112021012240 A BR 112021012240A BR 112021012240 A2 BR112021012240 A2 BR 112021012240A2
- Authority
- BR
- Brazil
- Prior art keywords
- wiskott
- aldrich syndrome
- stem cell
- gene therapy
- hematopoietic stem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02008—Hypoxanthine phosphoribosyltransferase (2.4.2.8)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich. a presente invenção refere-se a vetores de expressão compreendendo pelo menos duas sequências de ácido nucleico, a saber, uma sequência de ácido nucleico codificando um arni anti-hprt e uma sequência de ácido nucleico codificando uma proteína da síndrome de wiskott-aldrich. em algumas modalidades, o vetor de expressão é um vetor lentiviral auto-inativador. em algumas modalidades, a proteína da síndrome de wiskott-aldrich é utilizada para aliviar as patologias associadas à síndrome de wiskott-aldrich.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862784508P | 2018-12-23 | 2018-12-23 | |
PCT/US2019/068233 WO2020139796A1 (en) | 2018-12-23 | 2019-12-23 | Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021012240A2 true BR112021012240A2 (pt) | 2022-01-18 |
Family
ID=69326699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021012240A BR112021012240A2 (pt) | 2018-12-23 | 2019-12-23 | Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210316013A1 (pt) |
EP (1) | EP3897745A1 (pt) |
JP (1) | JP2022514955A (pt) |
KR (1) | KR20210118402A (pt) |
CN (1) | CN113518825A (pt) |
AU (1) | AU2019417697A1 (pt) |
BR (1) | BR112021012240A2 (pt) |
WO (1) | WO2020139796A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111093715A (zh) * | 2017-09-18 | 2020-05-01 | 儿童医院医疗中心 | 强绝缘子和其在基因递送中的用途 |
EP4329822A1 (en) | 2021-04-26 | 2024-03-06 | CSL Behring L.L.C. | Lentiviral vectors useful for the treatment of disease |
CN114990163A (zh) * | 2022-03-31 | 2022-09-02 | 中海峡(福建)细胞生物科技有限公司 | 用于干细胞基因修饰的慢病毒载体及其构建方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2216647A1 (en) | 1995-03-27 | 1996-10-03 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical agents containing methotrexate derivatives |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
US9023617B2 (en) | 2004-02-17 | 2015-05-05 | University Of Florida Research Foundation, Inc. | Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression |
SI1766010T1 (sl) | 2004-06-28 | 2011-06-30 | Univ Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo |
MX2007010008A (es) * | 2005-02-16 | 2008-01-18 | Lentigen Corp | Vectores lentivirales y su uso. |
WO2007098089A2 (en) | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs |
CN103849629B (zh) | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体 |
CA3066050A1 (en) | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
PL2499249T3 (pl) | 2009-11-12 | 2019-03-29 | Univ Western Australia | Cząsteczki antysensowne i sposoby leczenia patologii |
US20110294114A1 (en) | 2009-12-04 | 2011-12-01 | Cincinnati Children's Hospital Medical Center | Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells |
EP3799876A1 (en) * | 2011-04-20 | 2021-04-07 | The Regents of the University of California | Method for combined conditioning and chemoselection in a single cycle |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
RS57789B1 (sr) | 2012-09-06 | 2018-12-31 | Univ Chicago | Antisens polinukleotidi za indukovanje preskakanja egzona i postupci lečenja distrofija |
EP3662912A1 (en) | 2013-03-15 | 2020-06-10 | Sarepta Therapeutics, Inc. | Improved dosages of eteplirsen for treating duchenne muscular dystrophy |
WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
EP3011034B1 (en) * | 2013-06-17 | 2019-08-07 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
MX2016007328A (es) * | 2013-12-12 | 2017-07-19 | Broad Inst Inc | Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma. |
CN104805120A (zh) * | 2014-01-27 | 2015-07-29 | 苟德明 | 一种shRNA-Ago2共表达慢病毒RNAi载体、重组质粒及其构建方法 |
MX2016013964A (es) | 2014-04-25 | 2017-04-06 | Bluebird Bio Inc | Receptores de antigenos quimericos del promotor mnd. |
PL3294893T3 (pl) | 2015-05-13 | 2024-04-29 | Csl Behring Gene Therapy, Inc. | Bioprodukcja wektorów lentiwirusowych |
JP2018518196A (ja) | 2015-05-18 | 2018-07-12 | カリミューン, インコーポレーティッド | Hivの治療のための遺伝子治療法およびその使用 |
CA3012332A1 (en) * | 2016-02-19 | 2017-08-24 | The Regents Of The University Of California | Short hairpin rna (shrna734) and use of same to positively select and eliminate genetically modified cells |
US20190328901A1 (en) | 2016-06-17 | 2019-10-31 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
BR112020001059A2 (pt) * | 2017-07-18 | 2020-07-14 | Calimmune, Inc. | composições e métodos para o tratamento de beta-hemoglobinopatias |
CA3109924A1 (en) * | 2018-08-24 | 2020-02-27 | Csl Behring Gene Therapy, Inc. | Vector production in serum free media |
-
2019
- 2019-12-23 KR KR1020217023216A patent/KR20210118402A/ko unknown
- 2019-12-23 WO PCT/US2019/068233 patent/WO2020139796A1/en unknown
- 2019-12-23 EP EP19842992.0A patent/EP3897745A1/en active Pending
- 2019-12-23 AU AU2019417697A patent/AU2019417697A1/en active Pending
- 2019-12-23 BR BR112021012240A patent/BR112021012240A2/pt unknown
- 2019-12-23 JP JP2021536371A patent/JP2022514955A/ja active Pending
- 2019-12-23 CN CN201980092125.2A patent/CN113518825A/zh active Pending
-
2021
- 2021-06-21 US US17/353,586 patent/US20210316013A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019417697A1 (en) | 2021-07-08 |
EP3897745A1 (en) | 2021-10-27 |
WO2020139796A1 (en) | 2020-07-02 |
KR20210118402A (ko) | 2021-09-30 |
US20210316013A1 (en) | 2021-10-14 |
CN113518825A (zh) | 2021-10-19 |
JP2022514955A (ja) | 2022-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021012240A2 (pt) | Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich | |
CL2022001372A1 (es) | Construcciones para terapia génica con microdistrofina y uso de las mismas. | |
BR122021025194A8 (pt) | Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna | |
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
BR112016018598A2 (pt) | vetor de vírus adeno-associados | |
MX2020000676A (es) | Composiciones y metodos para tratar beta-hemoglobinopatias. | |
BR112018074325A2 (pt) | anticorpo para ligação a receptor de interleucina 4 | |
SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
BR112017013573A2 (pt) | rna de cadeia dupla, sequência de dna, cassete de expressão, vetor de terapia de gene, e, célula hospedeira. | |
MX2021010559A (es) | Polipéptidos efectores de crispr-cas y métodos de uso de estos. | |
MX2020004149A (es) | Variantes de desoxirribonucleasa (dnasa). | |
MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
MY197846A (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
BR112017028205A2 (pt) | molécula de rna, vetor, célula hospedeira, composição farmacêutica, kit, e, uso de uma ou mais utrs. | |
SA517381912B1 (ar) | "عناصر تنظيمية معدلة بعد الانتساخ لعلاج الالتهاب الكبدي pre | |
AR103646A1 (es) | ARNi VARIANTE PARA EL SILENCIAMIENTO GÉNICO | |
BR112017022322A2 (pt) | enzimas e aplicações das mesmas | |
BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
BR112018010639A2 (pt) | método de transfecção transitória para produção retroviral. | |
BR112018001121A2 (pt) | vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico | |
MX2022007858A (es) | Polipeptidos efectores crispr-cas y metodos de uso de estos. | |
CL2021002262A1 (es) | Composiciones y métodos para tratar laminopatías | |
AR114540A1 (es) | VARIANTE DE ARNi CONTRA a-SINUCLEÍNA | |
PH12020551191A1 (en) | Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector | |
EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута |